TP63 and ovarian cancer: Fig 7 also indicates that ACTL6A was remarkably coamplified with TP63 (p<0.001, log odds ratio>3) across ovarian cancer, esophageal cancer and lung adenocarcinoma. Moreover, BRD9 showed significant coamplification with TP63 (p<0.001 log odds ratio = 0.907).